Corporate Responsibility Report

Overview

The report describes Cytokinetics' 2025 transition to a commercial-stage company, marked by approval of MYQORZO, its first commercial medicine, and expansion of global operations. It also details Board oversight of corporate responsibility and reports 673 employees, USD 88.0 million in revenue, and 924 metric tons CO2e of market-based Scope 1 and 2 emissions. The report records 2,530 metric tons CO2e of partial Scope 3 emissions, 30% women on the Board, and zero workplace fatalities.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Ratings

GRI level

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services